Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | DUSP1 | P28562 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CETP | P11597 | 8/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249921 | 0.79 | MAPT (0.67) | MAPTTP53THRBSMN1; SMN2CETP | |
| SCHEMBL6231040 | 0.78 | MAPT (0.75) | MAPTTP53THRBSMN1; SMN2CETP | |
| SCHEMBL14096636 | 0.76 | DUSP1 (0.75) | MAPTTP53DUSP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12136722 | 0.75 | MAPT (0.81) | MAPTTP53THRBSMN1; SMN2CETP | |
| SCHEMBL9681997 | 0.75 | NPC1 (0.71) | MAPTTP53THRBSMN1; SMN2CETP | |
| SCHEMBL5457898 | 0.74 | ALDH1A1 (0.81) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20768089 | 0.73 | CETP (1.00) | MAPTTP53CETP | |
| SCHEMBL5713540 | 0.72 | EPHX1 (0.71) | MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL13977666 | 0.72 | MAPT (0.75) | MAPTTP53DUSP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15745638 | 0.72 | NPC1 (0.66) | MAPTTP53THRBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | MAPT 4038/4885TP53 308/4885THRB 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.